There are so many posts, I'm not sure if these poi
Post# of 153854
(Total Views: 574)
Posted On: 01/26/2022 7:31:15 AM
There are so many posts, I'm not sure if these points have been made. First I agree with the positive posts regarding NP. I think he did the best he did with what he had, that is, his personal and interpersonal skills. Also, he had the vision to advance LL to this point. Secondly, if there is any evidence of malfeasance or impropriety, I take back everything I just said. Third, I believe this is the most significant statement of the PR, other than the termination itself:
"Scott A. Kelly, M.D, Chairman of the Board and Chief Medical Officer of CytoDyn, stated, “Now is the right time for the next phase of CytoDyn’s evolution, as we focus on continuing the clinical progress of leronlimab and ultimately securing regulatory approval and commercialization. Our Board is fully focused on identifying the best possible candidate to lead the Company forward, and we are focusing our search on finding an individual with the appropriate experience and skillsets to maximize the potential of leronlimab for patients, partners, and shareholders."
So publicly at least, Dr. Kelly is saying that NP took the company as far as he could. In order to move Cytodyn forward scientifically, medically, politically, and commercially, the new CEO must have better sophistication as to bringing a small biotech public and getting its science approved by the appropriate entities. Commercial success should follow. To me, this appears to be a natural progression.
"Scott A. Kelly, M.D, Chairman of the Board and Chief Medical Officer of CytoDyn, stated, “Now is the right time for the next phase of CytoDyn’s evolution, as we focus on continuing the clinical progress of leronlimab and ultimately securing regulatory approval and commercialization. Our Board is fully focused on identifying the best possible candidate to lead the Company forward, and we are focusing our search on finding an individual with the appropriate experience and skillsets to maximize the potential of leronlimab for patients, partners, and shareholders."
So publicly at least, Dr. Kelly is saying that NP took the company as far as he could. In order to move Cytodyn forward scientifically, medically, politically, and commercially, the new CEO must have better sophistication as to bringing a small biotech public and getting its science approved by the appropriate entities. Commercial success should follow. To me, this appears to be a natural progression.
(3)
(0)